A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of Single and Multiple Administration of F230 Tablets in Healthy Adult Volunteers
Latest Information Update: 21 Apr 2025
At a glance
- Drugs F 230 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors Beijing Continent Pharmaceutical
Most Recent Events
- 28 Mar 2025 Status changed from planning to not yet recruiting.
- 13 Aug 2024 According to a Gyre Therapeutics media release, the company expects to initiate this trial in 2025.
- 03 Jun 2024 New trial record